Abstract
Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Current Pharmaceutical Biotechnology
Title: Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents
Volume: 1 Issue: 3
Author(s): S. D. Nuttall, R. A. Iring and P. J. Hudson
Affiliation:
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Abstract: Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Export Options
About this article
Cite this article as:
Nuttall D. S., Iring A. R. and Hudson J. P., Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents, Current Pharmaceutical Biotechnology 2000; 1 (3) . https://dx.doi.org/10.2174/1389201003378906
DOI https://dx.doi.org/10.2174/1389201003378906 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Gold Nanomaterials: From Preparation to Pharmaceutical Design and Application
Current Pharmaceutical Design Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
Anti-Cancer Agents in Medicinal Chemistry Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Expression of Heme Oxygenase-1 in Response to Proteasomal Inhibition
Protein & Peptide Letters Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Current Drug Targets The Role of Autophagy in the Gut Pathogens Clearance and Evasion
Current Protein & Peptide Science The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Current Medicinal Chemistry Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical Design Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry